Patents Assigned to University of Wurzburg
  • Evaluation of mantle cell lymphoma and methods related thereto
    Patent number: 11725248
    Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: August 15, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg, Oregon Health & Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and Research
    Inventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
  • Method for determining lymphoma type and providing treatment
    Patent number: 11646099
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: May 9, 2023
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Boatd of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barceloa, Institut D'Investigacions Biomédiques Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft feuer medizinische Forshung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • Survival predictor for diffuse large B cell lymphoma
    Patent number: 11028444
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: June 8, 2021
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Methods for identifying, diagnosing, and predicting survival of lymphomas
    Patent number: 10697975
    Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: June 30, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic de Barcelona, Julius-Maximilians-University of Würzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of London
    Inventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine S. Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa M. Rimsza, Thomas Miller, Thomas Grogan, Elias Campo Guerri, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emilio Montserrat, Victor Moreno, Andreas Zettl, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
  • METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS OF EXPRESSION PROFILING
    Publication number: 20200143906
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health & Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • METHOD FOR DETERMINING LYMPHOMA TYPE
    Publication number: 20200105364
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • Method for subtyping lymphoma types by means of expression profiling
    Patent number: 10607717
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 31, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health and Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • EVALUATION OF MANTLE CELL LYMPHOMA AND METHODS RELATED THERETO
    Publication number: 20190153539
    Abstract: The present invention provides methods of determining a survival predictor score of a subject having mantle cell lymphoma (MCL). The present invention also provides methods of predicting the survival outcome of a subject having MCL and provides methods of selecting a treatment for a subject having MCL.
    Type: Application
    Filed: April 20, 2017
    Publication date: May 23, 2019
    Applicants: The United States of America, as represented by the secretary, Dep. of Health and Human Service, British Columbia Cancer Agency Branch, Julius-Maximilians - University of Würzburg, Oregon Health and Science University, Hospital Clinic de Barcelona, Universitat de Barcelona, Oslo University Hospital HF, Board of Regents of the University of Nebraska, The Cleveland Clinic Foundation, Mayo Foundation for Medical Education and Research
    Inventors: Louis M. Staudt, David William Scott, George W. Wright, Andreas Rosenwald, Pau Abrisqueta, Rita Braziel, Elias Campo Guerri, Wing C. Chan, Joseph M. Connors, Jan Delabie, Diego Villa, Kai Fu, Randy D. Gascoyne, Timothy Greiner, Elaine S. Jaffe, Pedro Jares, Anja Mottok, German Ott, Lisa M. Rimsza, Graham Slack, Dennis Weisenburger, Erlend B. Smeland, James Robert Cook
  • SURVIVAL PREDICTOR FOR DIFFUSE LARGE B CELL LYMPHOMA
    Publication number: 20180245165
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Application
    Filed: April 27, 2018
    Publication date: August 30, 2018
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Arizona Regents on Behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa M. Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaløy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George W. Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • Survival predictor for diffuse large B cell lymphoma
    Patent number: 9970059
    Abstract: The invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: May 15, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Human Services, Arizona Board of Regents on behalf of the University of Arizona, Queen Mary University of London, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Oregon Health & Science University, University of Rochester, Hospital Clinic de Barcelona, Universitat de Barcelona, British Columbia Cancer Agency Branch, Julius-Maximilians-University of Würzburg
    Inventors: Lisa Rimsza, Andrew T. Lister, Wing C. Chan, Dennis Weisenburger, Jan Delabie, Erlend B. Smeland, Harald Holte, Stein Kvaloy, Rita M. Braziel, Richard I. Fisher, Pedro Jares, Armando Lopez-Guillermo, Elias Campo Guerri, Elaine S. Jaffe, Georg Lenz, Wyndham H. Wilson, George Wright, Sandeep S. Dave, Louis M. Staudt, Randy D. Gascoyne, Joseph M. Connors, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, German Ott
  • METHODS FOR IDENTIFYING, DIAGNOSING, AND PREDICTING SURVIVAL OF LYMPHOMAS
    Publication number: 20180011106
    Abstract: Gene expression data provides a basis for more accurate identification and diagnosis of lymphoproliferative disorders. In addition, gene expression data can be used to develop more accurate predictors of survival. The present invention discloses methods for identifying, diagnosing, and predicting survival in a lymphoma or lymphoproliferative disorder on the basis of gene expression patterns. The invention discloses a novel microarray, the Lymph Dx microarray, for obtaining gene expression data from a lymphoma sample. The invention also discloses a variety of methods for utilizing lymphoma gene expression data to determine the identity of a particular lymphoma and to predict survival in a subject diagnosed with a particular lymphoma. This information will be useful in developing the therapeutic approach to be used with a particular subject.
    Type: Application
    Filed: June 22, 2017
    Publication date: January 11, 2018
    Applicants: The United States of America, as represented by he Secretary, Department of Health and Human Servi, Board of Regents of the University of Nebraska, University of Rochester, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Fundacio Clinic, Hospital Clinic de Barcelona, Julius-Maximilians-University of Wurzburg, British Columbia Cancer Agency Branch, Oslo University Hospital HF, Queen Mary and Westfield College, University of London
    Inventors: Louis M. Staudt, George Wright, Sandeep Dave, Bruce Tan, John I. Powell, Wyndham Wilson, Elaine S. Jaffe, Wing C. Chan, Timothy C. Greiner, Dennis Weisenburger, James Armitage, Kai Fu, Richard I. Fisher, Lisa M. Rimsza, Thomas Miller, Thomas Grogan, Elias Campo Guerri, Silvia M. Bea, Itziar Salaverria, Armando Lopez-Guillermo, Emilio Montserrat, Victor Moreno, Andreas Zetti, German Ott, Hans-Konrad Muller-Hermelink, Andreas Rosenwald, Julie Vose, Randy Gascoyne, Joseph Connors, Erlend B. Smeland, Stein Kvaloy, Harald Holte, Jan Delabie, T. Andrew Lister
  • Inhibition of VWF - GPIb/V/IX interaction and platelet-collagen interaction for prevention and treatment of cerebral attacks
    Publication number: 20090311267
    Abstract: The invention relates generally to an anti-thrombotic treatment of occlusive syndromes in the cerebral vascular system causing cerebral infarct due to stroke or ischemic stroke, which is a major cause of death and permanent disability in industrialized countries. More particularly, the invention relates to a system and method of preventing and treating such occlusive syndromes in the cerebral vascular by inhibiting initial adhesion/attachment of platelets to the endothelium by preventing or inhibiting binding of von Willebrand factor to platelet glycoprotein Ib by administration of a subject in such need anti-glycoprotein Ib monovalent antibodies and/or anti-vWF monovalent antibodies, rather than by blocking the common pathway of platelet aggregation by blockade of platelet aggregation with anti-glycoprotein IIb/IIIa.
    Type: Application
    Filed: March 23, 2009
    Publication date: December 17, 2009
    Applicants: University of Wurzburg, Katholieke Universiteit Leuven, K.U. Leuven R&D
    Inventors: Guido Stoll, Christoph Kleinschnitz, Bernhard Nieswandt, Hans Deckmyn, Simon De Meyer